Navigation Links
aTyr Pharma to Present at ChinaBio(R) Investor Forum in Hong Kong
Date:3/16/2009

Dr. James Cai, President of Hong Kong-based subsidiary Pangu BioPharma to Speak

SAN DIEGO, March 16 /PRNewswire/ -- aTyr Pharma, a privately held biopharmaceutical company focused on discovery and development of an entirely new class of natural protein therapeutics (biologics) for multiple disease indications, announced today that it will participate at the ChinaBio(R) Investor Forum in Hong Kong on 19 March 2009. Dr. James Cai, Senior Vice President of Clinical Development a aTyr Pharma and President of the Hong Kong based subsidiary Pangu BioPharma, will give an overview of aTyr's Discovery and Development program in the afternoon on Thursday, March 19th. The event will take place at the Hong Kong Science Park (http://www.chinabiollc.com/events/CBIF2009-HK/overview).

"aTyr Pharma and its Hong Kong subsidiary, Pangu BioPharma, are exactly the types of companies we seek out to present at our events," said Greg Scott, president and founder of ChinaBio LLC, organizer of the ChinaBio(R) Investor Forums. "aTyr's platform is strongly rooted in novel science, and Pangu is leveraging the best of China and Hong Kong through its research efforts here. We expect that aTyr will be very attractive to the over 50 VCs attending the Investor Forum."

aTyr has successfully raised Series A and Series B funds from leading U.S. based venture capital firms, including Alta Partners, Cardinal Partners and Polaris Venture Partners. In addition to supporting the company's continued platform discovery efforts, aTyr's management team is also preparing for preclinical development and Phase I studies for their first biologics drug candidate.

aTyr Pharma and Pangu BioPharma have a novel platform of naturally occurring protein fragments that can be developed into biologic agents for treating a wide variety of diseases. Capitalizing on t
'/>"/>

SOURCE aTyr Pharma
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Med Discovery and Laborium Biopharma Extend Their Development Partnership to Include Mammalian Cell Culture Processes and Clinical Manufacturing for All Products in Med Discovery's Portfolio
2. Jina Ventures Advises Swiss Pharma Contract on Strategic Sale to Covance Inc
3. DOR BioPharma Appoints Brian L. Hamilton, MD, PhD as Chief Medical Officer
4. Lexicon Pharmaceuticals 2008 Annual Report to Stockholders Available Online
5. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results
6. VIA Pharmaceuticals Secures Financing Up to $10.0 Million
7. BioCis Pharma Starts Phase IIa Trial in Psoriasis
8. Helix BioPharma Form 20-F Registration Statement Declared Effective by SEC
9. Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results
10. Advance Nanotechs Owlstone Announces First Pharmaceutical Industry Order
11. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2008 Financial Results on Friday, March 13, 2009 at 8:30am EDT

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...SINGAPORE, Dec. 2 S*BIO Pte Ltd to... JAK2 inhibitor, SB1518, at The American Society o... New Orleans. ,, Data will be presented on the ...trial of SB1518 detailing its safety, tolerability...le in dose levels ranging from 100 to 600 mg. Thes...
(Date:12/2/2009)... SHANGHAI, Dec. 2 /PRNewswire-Asia/ -- The world i...n turmoil and uncertainty is part of many,business...dustry has been,relatively immune to the economic ... , During the midst of the difficult time...; Johnson inaugurated an R&D center in Shangha...
(Date:12/1/2009)... VILLAGE, Nev., Dec. 1 P...nounced revenue guidance for the fourth quarter en..., as compared with $69 million for the fourth quar...ts was the first of two installment payments of $1... quarter 2008 results was a one-time $1.8 million ...
(Date:12/1/2009)...TH, Mass., Dec. 1 Harvest Technolo... results from the company sponsored 60-patient cli...enter in Chennai, India using the company,s BMAC S...ritical Limb Ischemia (CLI). Sri Ramachandra Medic...iated institution based in Chennai, India and one ...
Breaking Biology Technology:S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 2Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 3PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 2PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 3Harvest Technologies Announces Trial Results in its India Study Using BMAC to Treat Patients With Non-Reconstructable Critical Limb Ischemia 2Harvest Technologies Announces Trial Results in its India Study Using BMAC to Treat Patients With Non-Reconstructable Critical Limb Ischemia 3
...fications, thereby providing scientists with a too...duction to drug discovery. However, this sophistic...ing the threat of engineered pathogens. New resear...ome Biology shows that computational tools could b...ally engineered bacteria in environmental samples....
...ISE, Fla., March 17 Bioheart, Inc.,(Nasdaq: BHRT...elop,autologous (patient-derived) cell therapies a...heart damage, today announced that company founder...transition from Executive,Chairman and become Chai...,serves as the company,s Chief Technology Officer ...
...rch 19 at 10:00 AM EDT, CEDAR KNOLLS, N.J., March... today announced its financial results for,the fou...isphere will host a conference call to discuss fou...ch 19, 2008. A live webcast of the conference,call...: http://www.emisphere.com .,The live conference ...
Other Biology Technology:On the trail of rogue genetically modified pathogens 2Bioheart Founder, Howard J. Leonhardt, Becomes Chairman of the Board of Directors 2Bioheart Founder, Howard J. Leonhardt, Becomes Chairman of the Board of Directors 3Bioheart Founder, Howard J. Leonhardt, Becomes Chairman of the Board of Directors 4Emisphere Technologies, Inc. Announces 2007 Fourth Quarter and Year End Financial Results 2Emisphere Technologies, Inc. Announces 2007 Fourth Quarter and Year End Financial Results 3Emisphere Technologies, Inc. Announces 2007 Fourth Quarter and Year End Financial Results 4Emisphere Technologies, Inc. Announces 2007 Fourth Quarter and Year End Financial Results 5Emisphere Technologies, Inc. Announces 2007 Fourth Quarter and Year End Financial Results 6Emisphere Technologies, Inc. Announces 2007 Fourth Quarter and Year End Financial Results 7Emisphere Technologies, Inc. Announces 2007 Fourth Quarter and Year End Financial Results 8
(Date:12/2/2009)..., , REDWOOD CITY, Calif., Dec. 2 /PRNews...rint identity and authentication solutions, today ...del of its DigitalPersona biometric fingerprint te...gitalPersona U.are.U® 4500HD offering allows ...kly identify users so that specific transactions c...
(Date:12/2/2009)..., , Before one of your muscles can twitch, before... nerve, a tiny floodgate of sortscalled an ion cha... organs to let in the chemical signals that spur t...nstitute of Standards and Technology (NIST) has al...e surface membrane for the first time, potentially...
(Date:12/2/2009)..., New York, NY, December 2, 2009 Commonly prescr...ment of asthma in pregnant women as well as pre-te...trum disorders, psychiatric pathology, cognitive p...ren, according to a new study published in the Dec...trics & Gynecology . , Beta 2 adrenergic agonist...
Breaking Biology News(10 mins):DigitalPersona Fingerprint Sensor Technology Ships on IBM SurePOS 500 Retail Systems 2Nervy research: Researchers take initial look at ion channels in a model system 2Treatments for asthma and pre-term labor may increase risk of autism in developing fetus 2IH Systems RIVA Top Pick for Directors of Pharmacy 57370 1IH Systems RIVA Top Pick for Directors of Pharmacy 57370 2HMS Awarded Third Party Liability Services Contract by Minnesota 57366 1Dr Drew and Drug Czar Host Online Chat 57362 1
...009) The Michael & Susan Dell Center for Advancem...chool of Public Health Austin Regional Campus will...eship in Child Health at 1:30 p.m. Thursday, April...e Center Amphitheater in Austin. , Obesity expe...biostatistics and epidemiology at the University o...
...astatic prostate cancer has shown considerable pro...hose disease has become resistant to current drugs...gues at several other institutions, including Memo... new drug to treat a particularly lethal form of t... cancer, or CRPC. Also referred to as hormone-refr...
...9, 2009 -- Four experts in soil carbon research, f...tunity farmers and foresters have to manage soil c...ate in voluntary markets. Agricultural and forest ...50 million metric tons of carbon dioxide (CO 2 ) e... gas emissions. , The briefing, "Down to Earth Ca...
Other Biology News:Annual Michael & Susan Dell lectureship in child health 2New drug shows promise in treating drug-resistant prostate cancer 2New drug shows promise in treating drug-resistant prostate cancer 3New drug shows promise in treating drug-resistant prostate cancer 4Down to Earth carbon science: Briefing April 15 in DC 2
Hybridization Buffer from BD Biosciences Pharmingen
Chicken Anti-Plants Thaumatin 2 Polyclonal Antibody, Unconjugated from Abcam
Proteinase K Buffer from BD Biosciences Pharmingen
Rabbit Anti-VEGF Receptor 2, phospho (Tyr1214) Polyclonal Antibody, Unconjugated from Abcam
Biology Products: